gdhc507md
$1,000
Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals
Drug and Pharmaceuticals
Industry Insights
Drug and Pharmaceuticals Insight Reports
Insight reports and market intelligence for Drug and Pharmaceuticals.
21 insights found
Page 1 of 2
gdph7874fsa
$125
Albany Molecular Research Inc (AMRI) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph756fsa
$125
F. Hoffmann-La Roche Ltd (ROG) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph7227fsa
$125
Sangamo Therapeutics Inc (SGMO) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph66492fsa
$125
Keryx Biopharmaceuticals Inc (KERX) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph66258fsa
$125
Acadia Pharmaceuticals Inc (ACAD) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph62115fsa
$125
Mymetics Corp (MYMX) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph58486fsa
$125
Amarin Corp Plc (AMRN) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph3904fsa
$125
AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph34546fsa
$125
CTI BioPharma Corp (CTIC) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph28303fsa
$125
Chugai Pharmaceutical Co Ltd (4519) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph18235fsa
$125
Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph8733fsa
$125
ICON Plc (ICLR) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph66540fsa
$125
BioCryst Pharmaceuticals Inc (BCRX) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph66532fsa
$125
Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph57129fsa
$125
Akorn Inc (AKRX) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph44899fsa
$125
Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals
gdph40168fsa
$125
Shire Plc (SHP) - Financial and Strategic SWOT Analysis Review
Drug and Pharmaceuticals